Relmada Therapeutics annual free cash flow
2013
2015
2016
2017
2018
2019
2020
Relmada Therapeutics Free Cash Flow (FCF) History (RLMD)
Relmada Therapeutics reported −$209.9M in free cash flow for fiscal 2020, a decrease of $112.9M from the previous fiscal year.
View full Relmada Therapeutics company overviewRelmada Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2020 | 2020-12-31 | −$209.9M | −$112.9M | — | — |
| 2019 · Dec 31 | 2019-12-31 | −$96.9M | −$90.9M | — | — |
| 2018 | 2018-06-30 | −$6.0M | $501,556 | — | — |
| 2017 | 2017-06-30 | −$6.5M | $7.2M | — | — |
| 2016 | 2016-06-30 | −$13.7M | $2.5M | — | — |
| 2015 | 2015-06-30 | −$16.3M | −$16.2M | — | — |
| 2013 | 2013-08-31 | −$13,659 | — | — | −266.31% |
Relmada Therapeutics quarterly free cash flow
Q1.14
Q1.14
Q2.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2018 | 2018-06-30 | −$2.3M | −$1.3M | — | — |
| Q3 2018 | 2018-03-31 | −$1.6M | $249,992 | — | — |
| Q2 2018 | 2017-12-31 | −$1.1M | $321,349 | — | — |
| Q1 2018 | 2017-09-30 | −$981,639 | $1.2M | — | — |
| Q4 2017 | 2017-06-30 | −$1.0M | $1.8M | — | — |
| Q3 2017 | 2017-03-31 | −$1.9M | $1.8M | — | — |
| Q2 2017 | 2016-12-31 | −$1.5M | $2.5M | — | — |
| Q1 2017 | 2016-09-30 | −$2.2M | $1.0M | — | — |
| Q4 2016 | 2016-06-30 | −$2.8M | $1.6M | — | — |
| Q3 2016 | 2016-03-31 | −$3.7M | $744,234 | — | — |
| Q2 2016 | 2015-12-31 | −$3.9M | $1.0M | — | — |
| Q1 2016 | 2015-09-30 | −$3.2M | −$884,454 | — | — |
| Q4 2015 | 2015-06-30 | −$4.5M | −$3.5M | — | — |
| Q3 2015 | 2015-03-31 | −$4.4M | −$4.0M | — | — |
| Q2 2015 | 2014-12-31 | −$5.0M | −$4.6M | — | — |
| Q1 2015 | 2014-09-30 | −$2.3M | — | — | — |
| Q2 2014 · Mar 31 | 2014-03-31 | −$1.0M | — | — | — |
| Q1 2014 · Dec 31 | 2013-12-31 | −$428,690 | — | — | — |
| Q1 2014 · Sep 30 | 2013-09-30 | −$409,462 | — | — | — |
Relmada Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$16.3M to −$209.9M, a net decrease of $193.6M. Relmada Therapeutics's latest reported quarter, Q4 2018, generated −$2.3M in free cash flow, a decrease of $1.3M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Relmada Therapeutics filings at SEC.gov ↗